Kate McKinley

Ms. McKinley is the former Chief Executive Officer (CEO) of Elevar Therapeutics, where she played a pivotal role in fundraising and the M&A activities that led to Elevar’s acquisition by HLB, Inc. Prior to the CEO role, she served as Elevar’s Chief Commercial Officer (CCO), where she built and led Elevar's global commercial, medical affairs, business development, manufacturing, supply chain, alliance management, and corporate communications organizations. Prior to joining Elevar, she was the Head of Marketing, Training, and the Hospital Channel at Dendreon, responsible for the first FDA approved cell-based cancer immunotherapy. Prior to Dendreon, Ms. McKinley was U.S. Head of Sales at AbbVie, leading the Oncology, Urology and Gynecology sales and field reimbursement organizations overseeing new product launch planning, and market expansion strategies. Ms. McKinley has over 20 years of experience in creating and leading the vision and strategic partnerships in the biopharmaceutical industry, positioning organizations for commercial success within startup, rapid-growth, and Fortune 100 environments. Ms. McKinley is a summa cum laude graduate of The University of Tulsa. She holds an M.B.A. from the university's Collins College of Business and a Bachelor of Science in Business Administration with degrees in Marketing, Management and Psychology. In addition to serving as a board director for Maxwell Biosciences, Ms. McKinley is also a strategic advisor to the Board of Derma Corporation and was previously a Board Director of Elevar Therapeutics and Hainan Pactil Advanced Therapeutics Company LTD.